Cargando…

Non-Steroidal Anti-Inflammatory Drugs Increase Cisplatin, Paclitaxel, and Doxorubicin Efficacy against Human Cervix Cancer Cells

This study shows that the non-steroidal anti-inflammatory drug (NSAID) celecoxib and its non-cyclooxygenase-2 (COX2) analogue dimethylcelecoxib (DMC) exert a potent inhibitory effect on the growth of human cervix HeLa multi-cellular tumor spheroids (MCTS) when added either at the beginning (“prevent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robledo-Cadena, Diana Xochiquetzal, Gallardo-Pérez, Juan Carlos, Dávila-Borja, Víctor, Pacheco-Velázquez, Silvia Cecilia, Belmont-Díaz, Javier Alejandro, Ralph, Stephen John, Blanco-Carpintero, Betsy Alejandra, Moreno-Sánchez, Rafael, Rodríguez-Enríquez, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765098/ https://www.ncbi.nlm.nih.gov/pubmed/33333716 http://dx.doi.org/10.3390/ph13120463

Ejemplares similares

Acetate Promotes a Differential Energy Metabolic Response in Human HCT 116 and COLO 205 Colon Cancer Cells Impacting Cancer Cell Growth and Invasiveness
por: Rodríguez-Enríquez, Sara, et al.
Publicado: (2021)

Seizure following chemotherapy (paclitaxel and cisplatin) in a patient of carcinoma cervix
por: Dana, Rohitashwa, et al.
Publicado: (2016)

Transcriptional Regulation of Energy Metabolism in Cancer Cells
por: Rodríguez-Enríquez, Sara, et al.
Publicado: (2019)

Doxorubicin, paclitaxel, and cisplatin based chemotherapy for the treatment of angiosarcoma: Two case reports
por: Lewcun, Joseph A., et al.
Publicado: (2020)

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
por: Sherman-Baust, Cheryl A, et al.
Publicado: (2011)

Physiological Role of Glutamate Dehydrogenase in Cancer Cells
por: Moreno-Sánchez, Rafael, et al.
Publicado: (2020)

Ecdysteroids Sensitize MDR and Non-MDR Cancer Cell Lines to Doxorubicin, Paclitaxel, and Vincristine but Tend to Protect Them from Cisplatin
por: Martins, Ana, et al.
Publicado: (2015)

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
por: Xu, Qiaoping, et al.
Publicado: (2021)

17-β Estradiol up-regulates energy metabolic pathways, cellular proliferation and tumor invasiveness in ER+ breast cancer spheroids
por: Pacheco-Velázquez, Silvia Cecilia, et al.
Publicado: (2022)

The distribution and retention of paclitaxel and doxorubicin in multicellular layer cultures
por: LEE, JOO-HO, et al.
Publicado: (2012)

A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells
por: Duan, Zhenfeng, et al.
Publicado: (2014)

Radiation Recall Dermatitis after Treatment with Paclitaxel and Cisplatin
por: Baek, Seung Woo, et al.
Publicado: (2012)

Effects of paclitaxel and cisplatin on in vitro ovarian follicle development
por: Kim, Yoon Young, et al.
Publicado: (2019)

Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
por: Stathopoulos, G. P., et al.
Publicado: (2010)

Cisplatin/dexrazoxane/doxorubicin: Neutropenia and thrombocytopenia: case report
Publicado: (2020)

Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice.
por: Webster, L. K., et al.
Publicado: (1996)

Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells
por: Xu, Feifei, et al.
Publicado: (2014)

Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer
por: Rajappa, Senthil, et al.
Publicado: (2018)

Preparation and characterization of an injectable thermosensitive hydrogel for simultaneous delivery of paclitaxel and doxorubicin
por: Rezazadeh, Mahboubeh, et al.
Publicado: (2018)

Remote loading paclitaxel–doxorubicin prodrug into liposomes for cancer combination therapy
por: Yu, Jiang, et al.
Publicado: (2020)

External Beam Therapy in a Four-Field Box Technique with Paclitaxel versus a Two-Field Technique with Cisplatin in Locally Advanced Carcinoma Cervix: A Phase II Monocentric Trial
por: Narayanan, Vijayakumar, et al.
Publicado: (2012)

Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
por: Nakao, Yuri, et al.
Publicado: (2020)

Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma
por: Park, Se Hoon, et al.
Publicado: (2006)

Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.
por: Budach, W., et al.
Publicado: (1994)

Role of microRNAs in regulation of doxorubicin and paclitaxel responses in lung tumor cells
por: Maharati, Amirhosein, et al.
Publicado: (2023)

Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study
por: Vaz-Luis, Ines, et al.
Publicado: (2020)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
por: Sandercock, J., et al.
Publicado: (1998)

Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma
por: Tu, Lingli, et al.
Publicado: (2013)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
por: de Jong, Loek A. W., et al.
Publicado: (2023)

PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix
por: Mann, Minakshi, et al.
Publicado: (2019)

Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice
por: Hsu, Fei-Ting, et al.
Publicado: (2015)

Codelivery of Doxorubicin and Paclitaxel by Cross-Linked Multilamellar Liposome Enables Synergistic Antitumor Activity
por: Liu, Yarong, et al.
Publicado: (2014)

Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac
por: Sudha, Thangirala, et al.
Publicado: (2017)

Co-Delivery of Paclitaxel and Doxorubicin by pH-Responsive Prodrug Micelles for Cancer Therapy
por: Jiang, Yanhua, et al.
Publicado: (2020)

Novel pH-responsive nanohybrid for simultaneous delivery of doxorubicin and paclitaxel: an in-silico insight
por: Alimohammadi, Ehsan, et al.
Publicado: (2021)

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
por: Mohell, N, et al.
Publicado: (2015)

Self‐Stabilized Hyaluronate Nanogel for Intracellular Codelivery of Doxorubicin and Cisplatin to Osteosarcoma
por: Zhang, Yi, et al.
Publicado: (2018)

Self‐Stabilized Hyaluronate Nanogel for Intracellular Codelivery of Doxorubicin and Cisplatin to Osteosarcoma
por: Zhang, Yi, et al.
Publicado: (2018)

Single and combined effects of cisplatin and doxorubicin on the human and mouse ovary in vitro
por: Lopes, Federica, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pdltoifeig6eqls04het85e8s4